12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Obinutuzumab regulatory update

The European Commission granted Orphan Drug designation for obinutuzumab from Roche to treat chronic lymphocytic leukemia (CLL). The humanized mAb against CD20 is in Phase...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >